Form 4: Xeris Biopharma CFO Steven Pieper Reports Tax-Related Share Withholding
SEC Form 4 Filing
Steven Pieper, CFO of Xeris Biopharma Holdings, reports the withholding of shares to cover income tax obligations related to vested Restricted Stock Units.
Summary
- On January 3, 2025, Steven Pieper, the Chief Financial Officer of Xeris Biopharma Holdings, Inc., had 32,059 shares of common stock withheld by the issuer to satisfy income tax obligations.
- This withholding was related to the net settlement of Restricted Stock Units (RSUs) that vested on the same date.
- The price per share for the withholding was $3.61.
- Following this transaction, Pieper directly owns 1,409,761 shares of Xeris Biopharma Holdings, Inc.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to tax obligations, and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax-related share withholding, which is common upon the vesting of stock-based compensation.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects standard executive compensation practices and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of transaction: Share withholding for tax obligations and vesting of Restricted Stock Units. |
| 01/07/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.